Travere Therapeutics (TVTX) Stock Forecast & Price Target

$15.06

+0.71 (+4.95%)

(As of 09/19/2024 ET)

Travere Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 13 Analyst Ratings

Based on 13 Wall Street analysts who have issued ratings for Travere Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 4 have given a hold rating, and 9 have given a buy rating for TVTX.

Consensus Price Target

$17.58
16.76% Upside

High Forecast	$25.00
Average Forecast	$17.58
Low Forecast	$9.00

According to the 13 analysts' twelve-month price targets for Travere Therapeutics, the average price target is $17.58. The highest price target for TVTX is $25.00, while the lowest price target for TVTX is $9.00. The average price target represents a forecasted upside of 16.76% from the current price of $15.06.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	10 Buy rating(s)
Hold	4 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$17.58	$15.67	$15.58	$28.50
Forecasted Upside	16.76% Upside	85.83% Upside	83.94% Upside	55.66% Upside

Get Travere Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.

Who are Nvidia’s New Silent Partners? (Ad)

Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.

I call these Nvidia’s “Silent Partners.”

TVTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TVTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Travere Therapeutics Stock vs. The Competition

Type	Travere Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.69	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	16.76% Upside	985.23% Upside	6.70% Upside
News Sentiment Rating	Positive News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/13/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$20.00 ➝ $23.00	+72.16%
9/10/2024	Canaccord Genuity Group 1 of 5 stars		Boost Target	Buy ➝ Buy	$18.00 ➝ $23.00	+82.68%
9/9/2024	Guggenheim 3 of 5 stars		Upgrade	Neutral ➝ Buy	$25.00	+127.69%
9/6/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Nochomovitz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$14.00 ➝ $23.00	+104.81%
9/6/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$18.00 ➝ $19.00	+91.34%
9/6/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$20.00 ➝ $23.00	+131.62%
Get the Latest News and Ratings for TVTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
8/2/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$11.00 ➝ $12.00	+32.30%
8/2/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$12.00 ➝ $14.00	+54.35%
8/2/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$13.00 ➝ $16.00	+73.16%
2/16/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $9.00	+8.43%
12/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$8.00 ➝ $10.00	+17.10%
9/22/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$30.00 ➝ $14.00	+89.19%
9/21/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Lugo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/22/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$30.00	+82.37%
5/5/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Neutral
10/20/2022	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$45.00 ➝ $38.00	+67.84%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:05 PM ET.

TVTX Forecast - Frequently Asked Questions

What is Travere Therapeutics' forecast for 2024?: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Travere Therapeutics is $17.58, with a high forecast of $25.00 and a low forecast of $9.00.
Should I buy or sell Travere Therapeutics stock right now?: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TVTX shares.
Does Travere Therapeutics's stock price have much upside?: According to analysts, Travere Therapeutics's stock has a predicted upside of 72.26% based on their 12-month stock forecasts.
Has Travere Therapeutics been upgraded by Wall Street analysts recently?: Over the previous 90 days, Travere Therapeutics's stock had 1 upgrade by analysts.
What analysts cover Travere Therapeutics?: Travere Therapeutics has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, Citigroup, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, and Wedbush in the past 90 days.
Do Wall Street analysts like Travere Therapeutics more than its competitors?: Analysts like Travere Therapeutics less than other "medical" companies. The consensus rating score for Travere Therapeutics is 2.69 while the average consensus rating score for "medical" companies is 2.77. Learn more on how TVTX compares to other companies.